Help-
Working together to make a difference
Find Us Here
Additions 2010
- Third PML case reported with Rituximab
- How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis
- Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis
- Futility of the autoimmune orthodoxy in multiple sclerosis research
- 1st Aimspro Case Studies published
- Virus Infection May Trigger Unusual Immune Cells to Attack Nerves in Multiple Sclerosis
- Teva sabotaged drug to save Copaxone sales, claims ProNeuron
- MS treatment in final clinical trial stage
- LDN may promote psychological well-
being as well as generalized health especially in autoimmune disorders - Simple eye test measures damage from multiple sclerosis
- Not all oligodendrocytes are equal?
- New discovery on cause of tremor
- Start opening veins for MS patients, MDs say
- Could the enzyme Pyruvate Kinase be key to MS remission during pregnancy?
- Cannabis based MS drug Sativex approved by British medical authorities
- Urinary Rehab Effective in MS
- July 1 launch of CCSVI research projects -
National MS Society USA - MS Society Canada - Immune System Helps Transplanted Stem Cells Navigate In Central Nervous System
- Cardiotoxicity & other adverse events associated with mitoxantrone for MS
- UK MS Society scraps MS residential respite care
- FDA panel backs Novartis pill for multiple sclerosis
- European MS nurse survey
- Persons with Balance Issues Related to Stroke, Brain Injuries or Multiple Sclerosis Find Relief in Boston
- In the pipeline: Advance tests for multiple sclerosis
- MS patients told it'll be years before treatment
- Controversial treatment creating bitterness in Canadian MS Society elections
- MS Society (Canada) board bid foiled for frustrated Multiple Sclerosis patients
- Cheese and Depression
- Changing thoughts key to battling even severe depression
- Meditation reduces the emotional impact of pain
- Multiple sclerosis and pregnancy: what does the patient think?
- Vitamin D blood tests could lose Ont. Funding
- Battling MS in Baghdad: Iraqi doctor uses stem cell therapies to help treat patients’ diseases
- Oral Drug Reduces Relapse Rates in Multiple Sclerosis (Fingolimod)
- MS sufferer benefits from Bee Venom Therapy
- The changing demographic pattern of multiple sclerosis epidemiology
- Changing thoughts key to battling even severe depression
- Vitamin D: hope on the horizon for MS prevention?
- Multiple sclerosis and solar exposure before the age of 15 years
- Radical treatment gives MS patient back his life. Recent report of old news!
- Twin Study Sheds Interesting Light on MS
- My M.E. Experience
- Insoluble dietary fibre, or roughage, not only keeps you regular -
Immune System - Nutrition - Three more cases of a rare brain infection in multiple sclerosis patients on Tysabri
- CCSVI Meeting 26th May 2010 MS National Centre North London
- There is no good way to give bad news!
- A diagnosis is an opinion and how that opinion affects the individual is an unknown
- Stem cell transplantation in multiple sclerosis: current status and future prospects
- Pediatric MS
- Teenage MS
- Stem cell therapy shows promise in small MS trial
- Networking power of the web shifting power balance between doctors and patients
- CCSVI -
Catalyst For Change - CCSVI -
False Dawns
April
- History of CCSVI
- Rituximab may be an effective treatment for secondary progressive Multiple Sclerosis
- 2 Types of MS, Study Reveals
- CCSVI -
Doctors who believe MS linked to damaged veins urge more testing - New data supporting Cladribine Tablets as a potential new therapeutic option
- Researchers claim safety concerns on Alemtuzumab -
Campeth® have been addressed - No New Safety Signals in Two-
Year Fingolimod Study - MS-
Related Fatigue Responds to Immunodulator - Switch from Interferon to Glatiramer Acetate
- New Ampyra data released at AAN Annual meeting
- First patient enrolled in head-
to- head study of MS treatments - Resistance training improves mood and fatigue in people with MS
- People with MS have higher risk of other medical conditions
- Study suggests sudden irreversible disability is rarely seen in relapsing remitting MS
- Glucosamine sulphate as an add-
on therapy in MS investigated - Smoking May Increase Risk of MS
- Study explores link between sunlight, multiple sclerosis
- Vitamin D 'triggers and arms' the immune system
- Drinking milk during pregnancy lowers risk of multiple sclerosis in children
- Low Vitamin D levels are associated with greater risk of MS relapse
- Copaxone(R) 15-
year study in Multiple Sclerosis patients demonstrates robust long- term efficacy and safety - FDA warns of brain risk from frequent Tysabri use. Tysabri
- US Food and Drug Administration (FDA) announced approval for dalfampridine (Ampyra,
Elan/Acorda Therapeutics) extended-
release tablets to improve walking in patients with multiple sclerosis (MS). Dalframpridine (originally known as Fampridine)
- Biogen Idec has announced the submission of a marketing authorization application
(MAA) to the European Medicines Agency for Fampridine Prolonged Release (Fampridine-
PR) tablets - The more you take the more likely a potentially deadly brain infection could occur Tysabri
- ‘Liberation Procedure’ Chronic Cerebrospinal Venous Insufficiency -
CCSVI - Aimspro® -
Designated ‘Orphan Status’ for the Treatment of Amyotrophic Lateral Sclerosis has been granted by the TGA and the FDA. ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig’s disease. - Review Paper -
www.sciencedirect.com/science - Daval International
- regulatoryaffairs
- sypharma.com
- therapeuticsdaily
- SF1019 -
CLASS ACTION COMPLAINT AND - JURY DEMAND - SF 1019 -
Law Suit Complaint for: - Violation of Securities Exchange Act
- Fraud and Fraud in the Inducement
- Breach of Contract
- Violation of Rico
- Conspiracy to Violate Rico
- Civil Conspiracy
- Unjust Enrichment
- Fraudulent Conveyance
- SF1019
- New drug without an approved new drug application seized by the FDA. Argyle Industries